As shown in Figure 1, J–O, and Supplemental Figure 1G, KRAS-mutant NSCLC cells including H23 and H1573 and KRAS-WT NSCLCs including H522 and H292 are responsive to PTX treatment while KRAS KD did not increase the sensitivity of H23 and H1573 NSCLC cells to PTX treatment. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.